Testing LFD-200 in healthy adults and adults with rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new drug, LFD-200, in healthy adults and in adults with moderate to severe rheumatoid arthritis who have active symptoms despite methotrexate. The goal is to see if it's safe and how it affects the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had rheumatoid arthritis for at least 6 months.
- You need to be between 18 and 75 years old.
- You must be taking methotrexate at a stable dose for at least 12 weeks.
- You must have active RA with at least 4 swollen and 4 tender joints.
- You cannot have serious infections, certain heart or lung conditions, or abnormal blood test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether ZB002 is safe in people, and how the body handles the drug. It includes both healthy volunteers and people with rheumatoid arthritis (RA) to see if the drug has a predictable blood level pattern.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.